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Abstract: Follicle stimulating hormone (FSH) receptors (FSHR) are physiologically expressed in the ovary and
testis. It is well known that FSHR are also expressed in gonadal cancers, but data regarding their incidence in
extra-gonadal tumors is scarce. Recently, the expression of FSHR in the vascular endothelium within different
human cancers was found, but nothing is yet known about FSHR appearance in non-gonadal endocrine tumors.
The present paper reports on the immunohistochemical detection of FSHR in human pituitary adenomas and
adrenal tumors. The study included samples of 28 pituitary adenomas and 37 adrenal tumors. Moreover, two
samples of non-tumoral adrenal glands were also studied. FSH receptor immunostaining was performed on paraf-
fin sections using the rabbit anti-human FSH-R polyclonal antibody raised against 1-190 amino acid sequence from
the human FSH-R (sc-13935). The pituitary adenomas were immunostained to reveal the pituitary hormones and
the proliferation marker Ki-67. In the pituitary adenomas, positive immunostaining with anti-FSHR antibody
occurred in the adenoma cells cytoplasm and endothelia of the intra- and peritumoral blood vessels. Cytoplasmic
immunostaining was found in the majority of investigated tumors, but the intensity of staining was weak to moder-
ate. There was some tendency towards a higher cytoplasmic FSHR score in tumors with higher Ki-67 index (atyp-
ical adenomas). In contrast to the cytoplasm, the FSHR immunostaining in blood vessels was strong and concerned
all the investigated samples. Strong FSHR immunostaining was present in the endothelium of intra- and/or peritu-
moral blood vessels in the majority of pheochromocytomas, approximately one half of the adrenocortical adenom-
as, and all cases of adrenal cancers. The immunostaining was detectable also in the tumoral cell cytoplasm in all but
one examined pheochromocytomas. All the investigated adrenocortical adenomas presented strong immunostain-
ing of cell membranes. No immunostained cell membranes were found in adrenal cancers. The positive immun-
ostaining was found in glandular cells, but not in blood vessels of non-tumoral adrenal cortex and medulla. Immu-
nostaining of FSHR often occurs in the endothelium of intra- and/or peritumoral blood vessels of pituitary ade-
nomas and benign and malignant adrenal tumors. The immunostaining may be also present in neoplastic cells.
A role of FSHR expression in these tumors, such as stimulation of angiogenesis or of cell proliferation, needs to be
clarified in further studies. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 3, 325–330)
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Introduction
FSH receptors (FSHR) are membrane receptors
transducing the biological signal of the follicle stimu-
lating hormone (follitropin, FSH) on its target cells.
FSHR are expressed in normal conditions in female
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and male gonads; in the granulosa cells of the ovary
and in Sertoli cells of the testis. They are known also
to be expressed in gonadal tumors, both in males and
females [for review see: 1]. Less is known about FSHR
expression in extra-gonadal tumors. Several tumors
have been shown to express luteinizing hormone/
/chorionic gonadotrophin receptors (LH/ CG-R) and
the tumorigenic action of LH and chorionic gonadot-
ropin (CG) has been hypothesized [1].
The expression of FSHR has been investigated by
means of polymerase chain reaction (PCR) and im-
munohistochemistry in the human prostate and pros-
tate cancers. The presence of FSHR in the normal
prostate and benign prostate hyperplasia has been
found, but the expression was higher in prostate can-
cer. In prostate cancer cell lines, FSHR were present
in an androgen resistant line PC3 but absent in an-
drogen-sensitive LNCaP cells [2]. Recently, Radu et
al. [3], using immunohistochemistry and in situ hy-
bridization, have reported the expression of FSHR
in intratumoral and peritumoral blood vessels in
a large series of human cancers, including prostate,
breast, colon, pancreas, urinary bladder, kidney, lung,
liver, stomach, testis and ovary. To the best of our
knowledge, FSHR expression has not been studied
to date in extra-gonadal endocrine tumors. The
present paper shows that FSHR are expressed also
in pituitary adenomas and adrenal tumors.
Material and methods
Tumor samples. Twenty eight pituitary adenomas and 37
adrenal tumors, surgically excised, and one post mortem
collected hyperplastic adrenal gland, were included in the
study.
The pituitary adenomas included five samples from pa-
tients with acromegaly, two prolactinomas, 17 clinically non-
functioning adenomas, and four corticotropinomas mani-
festing as Cushing’s disease. In the group of clinically non-
functioning pituitary adenomas (CNFPA), seven expressed
gonadotrophins, three expressed ACTH without the symp-
toms of Cushing’s disease (‘silent’ corticotropinomas), two
expressed growth hormone without the symptoms of ac-
romegaly (‘silent’ somatotropinomas), and five were pluri-
hormonal (they expressed GH/PRL/LH in two cases, a–sub-
unit/GH/PRL in one case, ACTH/LH in one case and GH/
/LH in one case). The adrenal tumors included eight pheo-
chromocytomas, 26 adrenocortical adenomas and three
adrenal cancers. Within the adrenocortical adenomas, four
were excised in patients suffering from Conn’s syndrome
and four in patients with Cushing’s syndrome; the remain-
ing 16 were nonfunctioning. Moreover, one sample of
adrenocortical hyperplasia from a female patient with
ACTH-dependent Cushing’s syndrome due to the ectopic
ACTH secretion by a neuroendocrine thymic tumor and
a sample of non-tumoral adrenal cortex adjacent to pheo-
chromocytoma tumor was also examined.
Immunohistochemistry. FSH receptor immunostaining was
performed using the rabbit anti-human FSH-R polyclonal
antibody sc-13935. This antibody was raised against 1-190
amino acid sequence from the human FSH-R. The anti-
body was purchased from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, USA) and its specificity had been approved
in earlier publications [4, 5]. The antibody was applied in
a working dilution of 1:100. Each pituitary adenoma was pre-
viously immunostained using the antibodies against the pi-
tuitary hormones and alpha-subunit (alpha-SU). More de-
tailed information on pituitary hormone immunohistochem-
istry was published in an earlier paper [6]. The hormone
immunohistochemistry, taken together with clinical data,
served to classify the pituitary adenoma samples. Addition-
ally, 16 pituitary adenomas were also immunostained with
anti-Ki-67 (MIB-1) antibody (Dako Cytomation, Glostrup,
Denmark). The visualization of primary antibodies was done
using either the StreptABComplex/HRP Duet (Dako Cy-
tomation, pituitary hormones and Ki-67) or the Dako REAL
EnVision Detection System (FSHR) following the proce-
dures recommended by the manufacturer. The intensity of
the immunoreaction for FSHR protein in the tumoral cells
cytoplasm was scored semiquantitatively using a descriptive
scale as follows: negative staining (score = 0), weak stain-
ing (score = 1), moderate staining (score = 2) and strong
staining (score = 3). The statistical comparison of scores
was performed by means of Student’s t test. For a positive
control, a biopsy sample of the human testis was immun-
ostained. For a negative control, the primary antibody was
omitted in the staining procedure.
The study was approved by the Local Bioethical Com-
mittee, decision number RNN/537/11/KB dated 14 June 2011.
Results
Pituitary adenomas
In pituitary adenomas, positive immunostaining with
anti-FSHR antibody occurred in adenoma cells cyto-
plasm and endothelia of the intra- and peritumoral
blood vessels. Cytoplasmic immunostaining was found
in the majority of investigated tumors (25/28) but the
intensity of staining was either weak (score = 1) or
moderate (score = 2, Figure 1). There was no appre-
ciable difference between primary and recurrent pi-
tuitary adenomas (mean scores ± SEM, 1.1 ± 0.15
and 1.25 ± 0.28, respectively). However, the higher
score of FSHR in tumors with Ki-67 index > 3 in com-
parison to those with Ki-67 < 3 was found (mean
scores ± SEM, 1.2 ± 0.2 and 1.8 ± 0.3, respectively,
p < 0.05). Our material was too scarce to relate the
FSHR expression in the tumoral cells cytoplasm with
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the hormonal phenotype of the investigated adenom-
as. In contrast to the cytoplasm, the FSHR immun-
ostaining in blood vessels is strong and concerned all
the investigated samples (Figure 2). However, in
13/28 of examined tumors, the immunostaining of the
endothelium was fragmentary, present in some but
not all vessels, and/or present only in limited areas of
the endothelium.
Pheochromocytomas
Strong FSHR immunostaining was present in the
endothelium of intra- and/or peritumoral blood ves-
sels in 5/8 pheochromocytomas (Figure 3). The im-
munostaining was detectable also in tumoral cell cy-
toplasm in all but one examined pheochromocytomas
(7/8, Figure 4). The cytoplasmic FSHR immunopos-
itivity was stronger than that observed in pituitary
adenomas, but comparable with that observed in the
sample of non-tumoral adrenal medulla and in three
fragments of the adrenal medulla adjacent to the
adrenocortical tumors.
Adrenocortical adenomas
FSHR immunostaining was present in the endotheli-
um of intra- and/or peritumoral blood vessels in
12/22 examined tumors (Figure 5). However, the immu-
nopositivity of the endothelium was mostly fragmen-
tary, present in some but not all vessels, and/or present
only in limited areas of the endothelium. There was
no difference between nonfunctioning and function-
ing adenomas: the incidence of endothelial immun-
ostaining was 7/14 and 5/8, respectively. All the in-
vestigated adrenocortical adenomas presented strong
immunostaining of cell membranes. Weak diffuse cy-
toplasmic staining was also present.
Figure 1. Moderate positive immunostaining of pituitary
adenoma cells (recurrent ‘silent’ corticotropinoma) with
the anti-FSHR antibody. Original magnification × 400
Figure 2. FSHR immunostained blood vessels in the
periphery of corticotropinoma. Original magnification × 400
Figure 3. FSHR immunostaining of endothelium in a small
artery in the periphery of pheochromocytoma.
Original magnification × 200
Figure 4. FSHR immunostaining of pheochromocytoma
cells. Positive immunostaining of cell membranes and
cytoplasm. Original magnification × 400
Adrenal cancer
In all cases of adrenal cancer, strong immunostain-
ing of the intratumoral blood vessels endothelium with
anti-FSHR antibody was noted. No immunostained
cell membranes were found. On the other hand, in
the cancer cells cytoplasm in two cases the FSHR
immunostaining was weak (score = 1) or moderate
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(score = 2), while in the remaining case it was strong
(score = 3, Figure 6).
Non-tumoral adrenal cortex and medulla
In both samples of non-tumoral adrenal cortex (one
sample from ectopic Cushing’s syndrome and one ad-
jacent to a pheochromocytoma), a strong immunostain-
ing with anti-FSHR antibody localized in adrenocorti-
cal cell membranes was found. On the other hand, the
cytoplasmic staining was negative or weak (score = 1).
In contrast, in the adrenal medulla the immunostain-
ing was only cytoplasmic but strong (score = 3, Figure
7). The blood vessels were mostly immunonegative.
Interestingly, moderate FSHR immunostaining was
noticed in the cytoplasm of sympathetic gangliocytes
localized in the adrenal gland capsule (Figure 8).
Discussion
The results presented above show, for the first time,
that FSHR expression is detectable by immunohis-
tochemistry in the intra- and peritumoral blood ves-
sels endothelia in the pituitary adenomas and adre-
nal tumors. This finding is compatible with the earli-
er data of Radu et al. [3], who made a similar obser-
vation in human cancers of different origins. In con-
trast to cancers examined by the quoted authors,
pituitary adenomas and adrenocortical adenomas are
benign tumors. Nevertheless, some pituitary adenom-
as may exhibit aggressive behavior, consisting in the
infiltration of the adjacent structures (invasiveness)
and high growth potential. Taken together, our find-
ings show that the expression of FSHR in blood ves-
sels is not correlated with the degree of tumor malig-
nancy. Radu et al. [3] showed that FSHR expression
was confined to peri- and intratumoral blood vessels,
but was absent in non-tumoral tissue samples, except
gonads and placenta. The lack of FSHR immunopo-
sitivity within the vessels of non-tumoral adrenal cor-
tex corroborate with the data cited above. On the oth-
er hand, FSHR immunostaining in the investigated
tumors was not confined to the vascular endothelia,
but appeared in the tumoral cells as well. In pituitary
Figure 5. Nonfunctioning adrenocortical adenoma. Strong
FSHR immunostaining of adenoma cell membranes and
vascular endothelium and weak immunostaining of
adenoma cell cytoplasm. Original magnification × 400
Figure 6. FSHR immunostaining in cytoplasm of tumor
cells and vascular wall in the adrenal cancer.
Original magnification × 400
Figure 7. Fragment of non-tumoral adrenal cortex and
medulla adjacent to pheochromocytoma tumor. Strong
immunostaining of medullar cells (left) and weaker immuno-
staining of cortical cells (right). Original magnification × 200
Figure 8. Gangliocytes situated in the adrenocortical
capsule. Immunostaining of perikarya can be seen.
Original magnification × 400
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adenomas, the cytoplasmic FSHR immunostaining
seems to be related to the tumor growth potential.
Interestingly, the FSHR expression was also found in
the non-tumoral adrenal cortex and medulla. The
question as to whether the normal adrenal gland is
a direct target for gonadotrophins remains unanswered.
The direct effects of both FSH and LH were described
as long ago as the 1960s [7–9]. The synergic action of
FSH and ACTH on adrenal cortex growth was found
in hypophysectomized–gonadectomized rats [8]. FSH
was also shown to stimulate directly adrenal regener-
ation in rats, whereas LH inhibited this process [9].
More recently, LH-dependent adrenal tumorigene-
sis has been demonstrated in transgenic mice express-
ing a viral oncogene [10]. Moreover, the aberrant ex-
pression of LH/CG receptors (but not of FSHR) in
the adrenal cortex may be responsible for ACTH-in-
dependent macronodular adrenal hyperplasia mani-
festing as Cushing’s syndrome [11]. An accidental
observation reported in the present paper, that the
anti-FSHR antibody reacted with the non-tumoral
adrenomedullar cells and peri-adrenal sympathetic
gangliocytes, is also interesting because this could be
linked with neurovascular disturbances accompany-
ing perimenopausal period in women, characterized
by high FSH levels. However, this finding needs fur-
ther studies to be relevant. We here recall an early
paper from our laboratory showing the degenerative
changes in sympathetic ganglia after FSH adminis-
tration in hypohysectomized-gonadectomized rats
[12]. If FSHR expressed in endocrine and other tu-
mors are functional, they may exhibit a similar action
to that occurring in normal gonads and gonadal tu-
mors. It is known that FSH, acting via its receptors,
stimulates the proliferation of ovarian granulosa cells
and increases vascular endothelial growth factor
(VEGF) secretion within the ovary, leading to enhanced
angiogenesis [13]. A similar observation was made with
ovarian cancer cells SK-OV-3) [14]. FSH also inhibits
ovarian cancer cell apoptosis by up-regulating survivin
and down-regulating programmed cell death gene 6
(PDCD6) and death receptor 5 (DR5) [15].
The formation of new blood vessels (angiogene-
sis) is a process determining the development of sol-
id tumors. VEGF, a specific mitogen of the endothe-
lial cells, belongs to the crucial factors involved in the
mechanism of angiogenesis. The inhibition of VEGF
expression or inhibition of its receptors has been sug-
gested as a promising way of treating tumors [16].
VEGF levels have been found to be elevated in the
blood of patients with pituitary tumors [17–19] and
adrenal tumors [20]. In pituitary adenomas, VEGF
receptors are expressed not only in endothelial cells
of intratumoral blood vessels, but also in tumoral cells
[21]. It has been suggested that VEGF in pituitary
adenomas acts not only as a stimulator of angiogene-
sis, but directly promotes the growth of tumoral cells.
Conclusion
Immunostaining of FSHR was found in the endothe-
lium of intra- and/or peritumoral blood vessels of pi-
tuitary adenomas and benign adrenal tumors (adreno-
cortical adenomas), as well as in potentially malig-
nant (pheochromocytomas) and malignant (cancers)
adrenal tumors. The immunostaining may be also
present in neoplastic cells. The role of FSHR expres-
sion in these tumors, such as stimulation of angio-
genesis or growth of tumor cells, needs further stud-
ies to be clarified.
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